Search

Displaying results 1911 - 1920 of 6198 in total
  1. Drug

    Ferric carboxymaltose

    go.drugbank.com/drugs/DB08917
    ApprovedInvestigational

    Ferric carboxymaltose is an iron replacement product and, chemically, an iron-carbohydrate complex. It was FDA approved on July 25, 2013.

  2. Drug

    Human Menstrual Blood-derived Stem Cells

    go.drugbank.com/drugs/DB15738
    Investigational

    ESCs are from the inner cell mass of blastocysts while ASCs are deposited into adult tissues with restricted differentiation potency but also a lack of tumorigenicity. … Because this is a non-invasive way to obtain stem cells, it is simple and easy to obtain the stem cells with an absence of ethical issues that may come from obtaining stem cells of the embryonic kind.

  3. Drug

    Olodaterol

    go.drugbank.com/drugs/DB09080
    ApprovedInvestigational

    Elevation of these two molecules induces bronchodilation by relaxation of airway smooth muscles. … Activation of the receptor stimulates an associated G protein which then activates adenylate cyclase, catalyzing the formation of cyclic adenosine monophosphate (cAMP) and protein kinase A (PKA).

  4. Drug

    Sebelipase alfa

    go.drugbank.com/drugs/DB11563
    ApprovedInvestigational

    This lipid accumulation can lead to end-organ damage in the form of liver dysfunction or malabsorption secondary to intestinal dysfunction. … It was first approved by both the FDA and EMA in 2015 and is marketed under the brand name Kanuma (Alexion Pharmaceuticals).[L39337,L39342]

  5. Drug

    Etranacogene dezaparvovec

    go.drugbank.com/drugs/DB16791
    ApprovedInvestigational

    [L45255] Etranacogene dezaparvovec was approved by the EMA in February 2023[L45439,L45444] and by Health Canada in October 2023.[L48801] … Hemophilia B - also called factor IX deficiency or Christmas disease - is an X-linked genetic disorder resulting in an absence or deficiency of clotting factor IX.

  6. Drug

    TAK-428

    go.drugbank.com/drugs/DB05499
    Experimental

    It is based on the novel concept that peripheral nervous tissue that was damaged by diabetes can be repaired and regenerated by stimulating an increase in neurotrophic factors.

  7. Drug

    Benzoctamine

    go.drugbank.com/drugs/DB09021
    Experimental

    It can be used as a sedative which does not depress the respiratory system, but rather stimulates it. … It can also be used as an anxiolytic with the same efficacy as chlordiazepoxide for treating anxiety neurosis.

  8. Drug

    Velpatasvir

    go.drugbank.com/drugs/DB11613
    ApprovedInvestigational

    Velpatasvir is a Direct-Acting Antiviral (DAA) medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV).

  9. Drug

    Baclofen

    go.drugbank.com/drugs/DB00181
    ApprovedInvestigational

    Although originally designed in 1962 to treat epilepsy, baclofen was not effective in treating this condition but instead was shown to reduce spasticity in selected patients. … [A245338] Baclofen was reintroduced in 1971 as a treatment for spasticity and was later approved by the FDA in 1977.

  10. Drug

    Cilastatin

    go.drugbank.com/drugs/DB01597
    ApprovedInvestigational

    The first combination product containing both drugs was approved by the FDA in November of 1985 under the trade name Primaxin, marketed by Merck & Co. … Cilastatin is an inhibitor of renal dehydropeptidase, an enzyme responsible for both the metabolism of thienamycin beta-lactam antibiotics as well as conversion of leukotriene D4 to leukotriene E4.